RU2555326C2 - ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА - Google Patents
ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА Download PDFInfo
- Publication number
- RU2555326C2 RU2555326C2 RU2011132118/15A RU2011132118A RU2555326C2 RU 2555326 C2 RU2555326 C2 RU 2555326C2 RU 2011132118/15 A RU2011132118/15 A RU 2011132118/15A RU 2011132118 A RU2011132118 A RU 2011132118A RU 2555326 C2 RU2555326 C2 RU 2555326C2
- Authority
- RU
- Russia
- Prior art keywords
- benzo
- dihydro
- cyclohepta
- pyridazin
- diamine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 102
- 208000037819 metastatic cancer Diseases 0.000 title claims abstract description 78
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title claims abstract description 78
- 238000002648 combination therapy Methods 0.000 title description 75
- 238000000034 method Methods 0.000 claims abstract description 154
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 111
- 201000011510 cancer Diseases 0.000 claims abstract description 69
- 239000000126 substance Substances 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract description 48
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 29
- 229960004316 cisplatin Drugs 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 12
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 9
- 229960003668 docetaxel Drugs 0.000 claims abstract description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 9
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims abstract description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 8
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001433 erlotinib Drugs 0.000 claims abstract description 8
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 8
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 6
- 229960000684 cytarabine Drugs 0.000 claims abstract description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims abstract description 5
- 229960004891 lapatinib Drugs 0.000 claims abstract description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims abstract description 5
- -1 6 , 7-dihydro-5H-benzo [6,7] cyclohepta [1,2-c] pyridazin-3-yl Chemical group 0.000 claims description 785
- 239000002246 antineoplastic agent Substances 0.000 claims description 53
- 229940127089 cytotoxic agent Drugs 0.000 claims description 52
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 21
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 49
- 239000003814 drug Substances 0.000 abstract description 11
- 230000001965 increasing effect Effects 0.000 abstract description 3
- KXMZDGSRSGHMMK-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl)-1,2,4-triazole-3,5-diamine Chemical group N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1CC2)=CC=C1CCC2N1CCCC1 KXMZDGSRSGHMMK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 231
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 139
- 125000001072 heteroaryl group Chemical group 0.000 description 133
- 125000000217 alkyl group Chemical group 0.000 description 114
- 125000000623 heterocyclic group Chemical group 0.000 description 106
- 125000003710 aryl alkyl group Chemical group 0.000 description 94
- 125000003107 substituted aryl group Chemical group 0.000 description 92
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 90
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 89
- 125000001188 haloalkyl group Chemical group 0.000 description 87
- 125000001424 substituent group Chemical group 0.000 description 81
- 125000005843 halogen group Chemical group 0.000 description 72
- 125000004093 cyano group Chemical group *C#N 0.000 description 64
- 229910052739 hydrogen Inorganic materials 0.000 description 64
- 239000001257 hydrogen Substances 0.000 description 64
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 63
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 63
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 60
- 125000002947 alkylene group Chemical group 0.000 description 55
- 150000003254 radicals Chemical class 0.000 description 54
- 125000003342 alkenyl group Chemical group 0.000 description 52
- 150000002431 hydrogen Chemical class 0.000 description 51
- 125000004043 oxo group Chemical group O=* 0.000 description 50
- 125000000464 thioxo group Chemical group S=* 0.000 description 50
- 229910052757 nitrogen Inorganic materials 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 40
- 125000006413 ring segment Chemical group 0.000 description 39
- 125000000304 alkynyl group Chemical group 0.000 description 38
- 238000003786 synthesis reaction Methods 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 37
- 125000003118 aryl group Chemical group 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 229940126062 Compound A Drugs 0.000 description 35
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- 125000004450 alkenylene group Chemical group 0.000 description 29
- 125000000262 haloalkenyl group Chemical group 0.000 description 29
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 29
- 239000004480 active ingredient Substances 0.000 description 28
- 125000000232 haloalkynyl group Chemical group 0.000 description 28
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 27
- 201000010099 disease Diseases 0.000 description 27
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 26
- 239000007787 solid Substances 0.000 description 25
- 208000026310 Breast neoplasm Diseases 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- 206010006187 Breast cancer Diseases 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 22
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 21
- 125000004419 alkynylene group Chemical group 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000002062 proliferating effect Effects 0.000 description 18
- 125000004429 atom Chemical group 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 229950009568 bemcentinib Drugs 0.000 description 16
- 238000002955 isolation Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
- 102000003929 Transaminases Human genes 0.000 description 15
- 108090000340 Transaminases Proteins 0.000 description 15
- 125000005605 benzo group Chemical group 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 13
- 208000009956 adenocarcinoma Diseases 0.000 description 13
- 150000005840 aryl radicals Chemical class 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 13
- 229940043355 kinase inhibitor Drugs 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 13
- 125000000168 pyrrolyl group Chemical group 0.000 description 13
- 206010027458 Metastases to lung Diseases 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-M carbamimidate Chemical compound NC([NH-])=O XSQUKJJJFZCRTK-UHFFFAOYSA-M 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 125000004076 pyridyl group Chemical group 0.000 description 11
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 11
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 230000009401 metastasis Effects 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 206010041823 squamous cell carcinoma Diseases 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 7
- 125000002785 azepinyl group Chemical group 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000003003 spiro group Chemical group 0.000 description 7
- 210000001685 thyroid gland Anatomy 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 6
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- RGZUCGKBLUSWKJ-UHFFFAOYSA-N 2,5,6,7-tetrahydrobenzo[1,2]cyclohepta[4,6-d]pyridazin-3-one Chemical compound C1CCC2=CC=CC=C2C2=NNC(=O)C=C21 RGZUCGKBLUSWKJ-UHFFFAOYSA-N 0.000 description 5
- NLTFNEOTIGWQDZ-UHFFFAOYSA-N 3-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound N1NC(N)=NC1(N)C(C=C1F)=CC=C1N1CCC(N2CCCC2)CC1 NLTFNEOTIGWQDZ-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 201000009273 Endometriosis Diseases 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 201000005969 Uveal melanoma Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000000460 chlorine Chemical group 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
- 229960002411 imatinib Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000005891 transamination reaction Methods 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- MIBBXYFRYDOZLE-UHFFFAOYSA-N 2,4,4a,5,6,7-hexahydrobenzo[1,2]cyclohepta[4,6-d]pyridazin-3-one Chemical compound C1CCC2=CC=CC=C2C2=NNC(=O)CC21 MIBBXYFRYDOZLE-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- PJMKITDIWYPIHU-UHFFFAOYSA-N 3-chloro-6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazine Chemical compound C1CCC2=CC=CC=C2C2=C1C=C(Cl)N=N2 PJMKITDIWYPIHU-UHFFFAOYSA-N 0.000 description 4
- QZIUIFLAIPSBTH-UHFFFAOYSA-N 6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-ylhydrazine Chemical compound C1CCC2=CC=CC=C2C2=C1C=C(NN)N=N2 QZIUIFLAIPSBTH-UHFFFAOYSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 208000007452 Plasmacytoma Diseases 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 125000003725 azepanyl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 4
- 150000003997 cyclic ketones Chemical class 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- QPDYHLMLYIEMPB-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-2-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC3=C(C4=CC=CC=C4CCC3)C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 QPDYHLMLYIEMPB-UHFFFAOYSA-N 0.000 description 3
- FLRNIPGMOWGCIH-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1 FLRNIPGMOWGCIH-UHFFFAOYSA-N 0.000 description 3
- 125000004913 2-ethylbutylamino group Chemical group C(C)C(CN*)CC 0.000 description 3
- 125000004897 3-methylbutylamino group Chemical group CC(CCN*)C 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 0 CN(C)c1nc(N(*)*)n[n]1* Chemical compound CN(C)c1nc(N(*)*)n[n]1* 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 3
- 101150047834 SNAI2 gene Proteins 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 150000003057 platinum Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
- 239000010802 sludge Substances 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KGKAYWMGPDWLQZ-UHFFFAOYSA-N 1,2-bis(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1CBr KGKAYWMGPDWLQZ-UHFFFAOYSA-N 0.000 description 2
- WPGGNDPDFCTMAA-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 WPGGNDPDFCTMAA-UHFFFAOYSA-N 0.000 description 2
- BGHQKPIRGUAWAV-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[6-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2N=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)CC1 BGHQKPIRGUAWAV-UHFFFAOYSA-N 0.000 description 2
- VOKXBNHCZJNBPA-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[4-(3,5-dimethylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1C(C)NC(C)CN1C(C=C1)=CC=C1NC1=NC(N)=NN1C(N=N1)=CC2=C1C1=CC=CC=C1CCC2 VOKXBNHCZJNBPA-UHFFFAOYSA-N 0.000 description 2
- XUFVEWOZYYHBEJ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-pyrido[4,5]cyclohepta[1,2-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CN=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 XUFVEWOZYYHBEJ-UHFFFAOYSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- CDSZSWIXGLZDTC-UHFFFAOYSA-N 3-[4-(4-cyclohexylpiperazin-1-yl)-3-fluorophenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound N1NC(N)=NC1(N)C(C=C1F)=CC=C1N1CCN(C2CCCCC2)CC1 CDSZSWIXGLZDTC-UHFFFAOYSA-N 0.000 description 2
- RHQMOXDFLGOSLE-UHFFFAOYSA-N 3-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound N1NC(N)=NC1(N)C1=CC=C(N2CCC(CC2)N2CCCC2)C=C1 RHQMOXDFLGOSLE-UHFFFAOYSA-N 0.000 description 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
- HQCYEGXUTFYYDM-UHFFFAOYSA-N 4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]-n-(2-pyrrolidin-1-ylethyl)benzamide Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C(=O)NCCN1CCCC1 HQCYEGXUTFYYDM-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- KWHUHTFXMNQHAA-UHFFFAOYSA-N 6,7,8,9-tetrahydrobenzo[7]annulen-5-one Chemical compound O=C1CCCCC2=CC=CC=C12 KWHUHTFXMNQHAA-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 230000000970 DNA cross-linking effect Effects 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150022345 GAS6 gene Proteins 0.000 description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 2
- 102100020870 La-related protein 6 Human genes 0.000 description 2
- 108050008265 La-related protein 6 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000008601 Polycythemia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000009527 Refractory anemia Diseases 0.000 description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101150098329 Tyro3 gene Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 150000004716 alpha keto acids Chemical class 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical group C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000002210 biocatalytic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229960002412 cediranib Drugs 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960000578 gemtuzumab Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 2
- 229960004616 medroxyprogesterone Drugs 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical group N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- 229940002005 zometa Drugs 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- SATZEVSULNTUKS-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-(5,5-dimethylspiro[1,3-dioxane-2,7'-6,8,9,10-tetrahydro-5h-cycloocta[b]pyridine]-3'-yl)-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1CC2)=CN=C1CCCC12OCC(C)(C)CO1 SATZEVSULNTUKS-UHFFFAOYSA-N 0.000 description 1
- YTYFSSKNZNOWFL-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-spiro[1,3-dioxolane-2,6'-5,7,8,9-tetrahydrocyclohepta[b]pyridine]-3'-yl-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCCC12OCCO1 YTYFSSKNZNOWFL-UHFFFAOYSA-N 0.000 description 1
- CYJRBPDAKRBCRL-UHFFFAOYSA-N 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-3-n-spiro[1,3-dioxolane-2,7'-5,6,8,9-tetrahydrocyclohepta[b]pyridine]-3'-yl-1,2,4-triazole-3,5-diamine Chemical compound N1=C(Cl)N=C2C(C)=CSC2=C1N(C(=N1)N)N=C1NC(C=C1CC2)=CN=C1CCC12OCCO1 CYJRBPDAKRBCRL-UHFFFAOYSA-N 0.000 description 1
- ZQPIWWJWCRLTPW-UHFFFAOYSA-N 1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-3-N-[3-fluoro-4-[methyl(piperidin-4-ylmethyl)amino]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C=1C=C(NC2=NN(C(N)=N2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C=C(F)C=1N(C)CC1CCNCC1 ZQPIWWJWCRLTPW-UHFFFAOYSA-N 0.000 description 1
- JLZPTRDWNLWPCG-UHFFFAOYSA-N 1-(5,6-dihydro-[1]benzoxepino[5,4-c]pyridazin-3-yl)-3-n-[2-(pyrrolidin-1-ylmethyl)-1,3-benzoxazol-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4OCCC=3C=2)C(N)=NC=1NC(C=C1N=2)=CC=C1OC=2CN1CCCC1 JLZPTRDWNLWPCG-UHFFFAOYSA-N 0.000 description 1
- RFXXLGXDRVGHSV-UHFFFAOYSA-N 1-(5,6-dihydro-[1]benzoxepino[5,4-c]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4OCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 RFXXLGXDRVGHSV-UHFFFAOYSA-N 0.000 description 1
- FBVAAXLPLJJZCW-UHFFFAOYSA-N 1-(5,6-dihydro-[1]benzoxepino[5,4-c]pyridazin-3-yl)-3-n-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4OCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1N(CC1)CCC1N1CCCC1 FBVAAXLPLJJZCW-UHFFFAOYSA-N 0.000 description 1
- HUSGAGAKMDNVGZ-UHFFFAOYSA-N 1-(5,6-dihydro-[1]benzoxepino[5,4-c]pyridazin-3-yl)-3-n-[4-[2-(dimethylamino)ethyl]-2,3-dihydro-1,4-benzoxazin-7-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1COC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC=2C=C3OCCN(C3=CC=2)CCN(C)C)=N1 HUSGAGAKMDNVGZ-UHFFFAOYSA-N 0.000 description 1
- NYAOQSNRIZOWPK-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[1,2]cyclohepta[3,4-d]pyrimidin-4-yl)-3-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2C3=C(C4=CC=CC=C4CCC3)N=CN=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 NYAOQSNRIZOWPK-UHFFFAOYSA-N 0.000 description 1
- SIEZORJWGSONCR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-2-yl)-3-n-[3-methyl-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2N=NC3=C(C4=CC=CC=C4CCC3)C=2)=CC=C1N(CC1)CCC1N1CCCC1 SIEZORJWGSONCR-UHFFFAOYSA-N 0.000 description 1
- VTORQVMLXVVZCN-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C3CNCCC3=CC=2)N=C1N VTORQVMLXVVZCN-UHFFFAOYSA-N 0.000 description 1
- UKXOTYOATJGLSB-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(2,3,4,5-tetrahydro-1-benzoxepin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C3CCCCOC3=CC=2)N=C1N UKXOTYOATJGLSB-UHFFFAOYSA-N 0.000 description 1
- OCKADWMDMJVYIJ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(3,4-dihydro-2h-1,5-benzodioxepin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C3OCCCOC3=CC=2)N=C1N OCKADWMDMJVYIJ-UHFFFAOYSA-N 0.000 description 1
- BZDJSSYPKKXGFU-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(4-iodophenyl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC1=CC=C(I)C=C1 BZDJSSYPKKXGFU-UHFFFAOYSA-N 0.000 description 1
- VXIHFCBJBJJQRR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(6-methyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CN=C3CCN(CC3=C2)C)=N1 VXIHFCBJBJJQRR-UHFFFAOYSA-N 0.000 description 1
- QVJKXKDAENTBIW-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C2)=CN=C1CCC2N1CCCC1 QVJKXKDAENTBIW-UHFFFAOYSA-N 0.000 description 1
- ZWRVVTUGYIFBIS-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-(7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1CC2)=CN=C1CCC2N1CCCC1 ZWRVVTUGYIFBIS-UHFFFAOYSA-N 0.000 description 1
- ZWRVVTUGYIFBIS-QHCPKHFHSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@@H]2CCC3=NC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 ZWRVVTUGYIFBIS-QHCPKHFHSA-N 0.000 description 1
- HDGUWDFZAUVUCE-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[2-(1-methylpiperidin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCC1N1CC2=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=C2CC1 HDGUWDFZAUVUCE-UHFFFAOYSA-N 0.000 description 1
- VIOCJDARXMMAAI-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CN=C1N(CC1)CCC1N1CCCC1 VIOCJDARXMMAAI-UHFFFAOYSA-N 0.000 description 1
- WXJFFENAPPZJER-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[2-[(dimethylamino)methyl]-3h-benzimidazol-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC=2C=C3N=C(NC3=CC=2)CN(C)C)=N1 WXJFFENAPPZJER-UHFFFAOYSA-N 0.000 description 1
- HTYLYPQNDMZXJU-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[2-[4-(piperidin-1-ylmethyl)piperidin-1-yl]pyrimidin-5-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CN=C1N(CC1)CCC1CN1CCCCC1 HTYLYPQNDMZXJU-UHFFFAOYSA-N 0.000 description 1
- CMZSMLCMONGBEB-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrol-5-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CC=C(C(=C2)F)N2CC3CCN(C3C2)C)=N1 CMZSMLCMONGBEB-UHFFFAOYSA-N 0.000 description 1
- ADLDJSALRIXCQC-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(1-propyl-3,3a,4,6,7,7a-hexahydro-2h-pyrrolo[3,2-c]pyridin-5-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CC=C(C(=C2)F)N2CC3CCN(C3CC2)CCC)=N1 ADLDJSALRIXCQC-UHFFFAOYSA-N 0.000 description 1
- JXZNQLQHTPVAOJ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(3-pyrrolidin-1-ylazepan-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(C1)CCCCC1N1CCCC1 JXZNQLQHTPVAOJ-UHFFFAOYSA-N 0.000 description 1
- RLYJDTLMOQFUKO-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(3-pyrrolidin-1-ylazetidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(C1)CC1N1CCCC1 RLYJDTLMOQFUKO-UHFFFAOYSA-N 0.000 description 1
- LEMHLYVLEXKPBD-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(3-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(C1)CCCC1N1CCCC1 LEMHLYVLEXKPBD-UHFFFAOYSA-N 0.000 description 1
- FSIBRWFMWUPMAG-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-methyl-2-piperidin-4-ylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1N(C)CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)C1C1CCNCC1 FSIBRWFMWUPMAG-UHFFFAOYSA-N 0.000 description 1
- YFQXRVAFFCLMKC-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-methyl-3-phenylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound CN1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1C1=CC=CC=C1 YFQXRVAFFCLMKC-UHFFFAOYSA-N 0.000 description 1
- RQNUAVWDWXROAZ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 RQNUAVWDWXROAZ-UHFFFAOYSA-N 0.000 description 1
- ISOLZQPXVJMEJC-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylazepan-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCCC1N1CCCC1 ISOLZQPXVJMEJC-UHFFFAOYSA-N 0.000 description 1
- OPRHZHGYBWQEOR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-3-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CC=C(C(=C2)F)C2NCC3CN(CC32)C)=N1 OPRHZHGYBWQEOR-UHFFFAOYSA-N 0.000 description 1
- PEVLJSWYRHYLPO-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(5-propyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-3-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CC=C(C(=C2)F)C2NCC3CN(CC32)CCC)=N1 PEVLJSWYRHYLPO-UHFFFAOYSA-N 0.000 description 1
- MPPOTFBGJJWYNY-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1N(C)CCC11CN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1 MPPOTFBGJJWYNY-UHFFFAOYSA-N 0.000 description 1
- VCKOGZZLDMZWNG-FQEVSTJZSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[(3s)-3-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H]1CCN(C1)C1=CC=C(C=C1F)NC=1N=C(N(N=1)C=1N=NC=2C3=CC=CC=C3CCCC=2C=1)N)N1CCCC1 VCKOGZZLDMZWNG-FQEVSTJZSA-N 0.000 description 1
- FERIKOUVDNFNRL-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[4-(4-methylpiperidin-1-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CC(C)CCN1C1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1 FERIKOUVDNFNRL-UHFFFAOYSA-N 0.000 description 1
- LWLPONCUHUWIDF-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[4-(4-propan-2-ylpiperazin-1-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C(C)C)CCN1C1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1 LWLPONCUHUWIDF-UHFFFAOYSA-N 0.000 description 1
- JFCNGEOTLXCCOQ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[4-(5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-3-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC2=CC=C(C(=C2)F)N2CCC(CC2)C2NCC3CN(CC32)C)=N1 JFCNGEOTLXCCOQ-UHFFFAOYSA-N 0.000 description 1
- MZJWTZVNLUGKSN-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-fluoro-4-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1CN1CCCC1 MZJWTZVNLUGKSN-UHFFFAOYSA-N 0.000 description 1
- UKNZKTXPUPEUPZ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-methyl-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)=CC=C1N(CC1)CCC1N1CCCC1 UKNZKTXPUPEUPZ-UHFFFAOYSA-N 0.000 description 1
- UKRLZOYEHIRPGD-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)C)CC1 UKRLZOYEHIRPGD-UHFFFAOYSA-N 0.000 description 1
- XMDOKWKFDAZVGT-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(1-methylpiperidin-3-yl)oxyphenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1N(C)CCCC1OC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 XMDOKWKFDAZVGT-UHFFFAOYSA-N 0.000 description 1
- DYTKWJBNPMZIRQ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(1-methylpiperidin-4-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCC1C(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 DYTKWJBNPMZIRQ-UHFFFAOYSA-N 0.000 description 1
- MRKZYBFKRVVJOK-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 MRKZYBFKRVVJOK-UHFFFAOYSA-N 0.000 description 1
- GKSRUWDPWONDBU-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(3,5-dimethylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1C(C)NC(C)CN1C(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 GKSRUWDPWONDBU-UHFFFAOYSA-N 0.000 description 1
- OOYGLPANQUROHM-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(3-morpholin-4-ylprop-1-enyl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C=CCN1CCOCC1 OOYGLPANQUROHM-UHFFFAOYSA-N 0.000 description 1
- GXVFKEATHGXPHQ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(3-piperidin-1-ylprop-1-enyl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C=CCN1CCCCC1 GXVFKEATHGXPHQ-UHFFFAOYSA-N 0.000 description 1
- HKZRQYRZBLOLKK-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(3-pyrrolidin-1-ylprop-1-enyl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C=CCN1CCCC1 HKZRQYRZBLOLKK-UHFFFAOYSA-N 0.000 description 1
- LXBUXLGQCKDMLW-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(4-methylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 LXBUXLGQCKDMLW-UHFFFAOYSA-N 0.000 description 1
- XNPCDTGSBNXLFV-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)-3-(trifluoromethyl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C(F)(F)F)=CC=C1N(CC1)CCC1N1CCCC1 XNPCDTGSBNXLFV-UHFFFAOYSA-N 0.000 description 1
- NMFDQVKNFCNLJR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1N(CC1)CCC1N1CCCC1 NMFDQVKNFCNLJR-UHFFFAOYSA-N 0.000 description 1
- OUJUSSZYLJJXHK-HXUWFJFHSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1[C@H](N(C)C)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 OUJUSSZYLJJXHK-HXUWFJFHSA-N 0.000 description 1
- TZNJFUQUZXEKAW-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 TZNJFUQUZXEKAW-UHFFFAOYSA-N 0.000 description 1
- OYUASDJGNHRHRM-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C(C)C)CCN1CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 OYUASDJGNHRHRM-UHFFFAOYSA-N 0.000 description 1
- AMWLJPQOXJCQEH-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1CN(CC1)CCC1N1CCCC1 AMWLJPQOXJCQEH-UHFFFAOYSA-N 0.000 description 1
- QMUHIFICJWGHJC-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound CC1(C)CCCC(C)(C)N1CCOC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 QMUHIFICJWGHJC-UHFFFAOYSA-N 0.000 description 1
- RZRJPRKUOHCRDE-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[2-(dimethylamino)ethyl]-2,3-dihydro-1,4-benzoxazin-7-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(N)=NC(NC=2C=C3OCCN(C3=CC=2)CCN(C)C)=N1 RZRJPRKUOHCRDE-UHFFFAOYSA-N 0.000 description 1
- ZLADNKQSPFMAKG-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-(4-methylpiperazin-1-yl)prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1CC=CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 ZLADNKQSPFMAKG-UHFFFAOYSA-N 0.000 description 1
- XHDPMQZROWMZDV-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-(4-piperidin-1-ylpiperidin-1-yl)prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C=CCN(CC1)CCC1N1CCCCC1 XHDPMQZROWMZDV-UHFFFAOYSA-N 0.000 description 1
- ONLCVQQQZRHPLR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-(4-propan-2-ylpiperazin-1-yl)prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C(C)C)CCN1CC=CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 ONLCVQQQZRHPLR-UHFFFAOYSA-N 0.000 description 1
- GUHDLZQWHMTEIQ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-(4-pyrrolidin-1-ylpiperidin-1-yl)prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C=CCN(CC1)CCC1N1CCCC1 GUHDLZQWHMTEIQ-UHFFFAOYSA-N 0.000 description 1
- FXCWVVZTVZXCLU-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-[3-(dimethylamino)pyrrolidin-1-yl]prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(C)C)CCN1CC=CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 FXCWVVZTVZXCLU-UHFFFAOYSA-N 0.000 description 1
- AMCWNGPEZOROQW-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]prop-1-enyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(CC=CC=2C=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)CC1 AMCWNGPEZOROQW-UHFFFAOYSA-N 0.000 description 1
- WNCHBBUGRKFVCQ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[4-(dimethylamino)piperidin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N(C)C)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 WNCHBBUGRKFVCQ-UHFFFAOYSA-N 0.000 description 1
- MGCXKGCXRKGGDP-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[4-[4-(dipropylamino)piperidin-1-yl]-3-fluorophenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N(CCC)CCC)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 MGCXKGCXRKGGDP-UHFFFAOYSA-N 0.000 description 1
- GRHJTHPMZXZCIH-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC2=NN(C(N)=N2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)=CN=C1N(CC1)CCC1N1CCCC1 GRHJTHPMZXZCIH-UHFFFAOYSA-N 0.000 description 1
- ZSNPQORTKOFWSZ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 ZSNPQORTKOFWSZ-UHFFFAOYSA-N 0.000 description 1
- YELAIOFSFQREGP-WEVVVXLNSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[6-[(e)-3-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C\C=C\C=2N=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)CC1 YELAIOFSFQREGP-WEVVVXLNSA-N 0.000 description 1
- AIDWUXDCRIIJQR-UXBLZVDNSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[6-[(e)-3-[4-(dimethylamino)piperidin-1-yl]prop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N(C)C)CCN1C\C=C\C(N=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 AIDWUXDCRIIJQR-UXBLZVDNSA-N 0.000 description 1
- RPWIUOBXMWRWSX-YRNVUSSQSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[6-[(e)-3-piperidin-1-ylprop-1-enyl]pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1\C=C\CN1CCCCC1 RPWIUOBXMWRWSX-YRNVUSSQSA-N 0.000 description 1
- BJGOBBYEQYHWKX-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-pyridin-3-yl-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC1=CC=CN=C1 BJGOBBYEQYHWKX-UHFFFAOYSA-N 0.000 description 1
- JBXMQQXZSVTIPJ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1C(NC=2C=C3CNCCC3=CC=2)=NC(N)=N1 JBXMQQXZSVTIPJ-UHFFFAOYSA-N 0.000 description 1
- IVLMBZDHTGVWDO-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[2-(1-methylpiperidin-4-yl)-3,4-dihydro-1h-isoquinolin-7-yl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCC1N1CC2=CC(NC=3N(N=C(N)N=3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=C2CC1 IVLMBZDHTGVWDO-UHFFFAOYSA-N 0.000 description 1
- OPFJCHGSKQEWOB-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[3-fluoro-4-(3-pyrrolidin-1-ylazetidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C=1C=2CCCC3=CC=CC=C3C=2N=NC=1N1N=C(N)N=C1NC(C=C1F)=CC=C1N(C1)CC1N1CCCC1 OPFJCHGSKQEWOB-UHFFFAOYSA-N 0.000 description 1
- HUXKNJVFPBUAAT-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[3-fluoro-4-(4-methyl-2-piperidin-4-ylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1N(C)CCN(C=2C(=CC(NC=3N(N=C(N)N=3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)C1C1CCNCC1 HUXKNJVFPBUAAT-UHFFFAOYSA-N 0.000 description 1
- LXXJRQGJAIJQCO-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(N)=NN1C(N=N1)=CC2=C1C1=CC=CC=C1CCC2 LXXJRQGJAIJQCO-UHFFFAOYSA-N 0.000 description 1
- JPCHRSPBCAAKGY-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[3-fluoro-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1N(C)CCC11CN(C=2C(=CC(NC=3N(N=C(N)N=3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CC1 JPCHRSPBCAAKGY-UHFFFAOYSA-N 0.000 description 1
- JHIOXBBIOBYIDR-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2C(=CC(NC=3N(N=C(N)N=3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)C)CC1 JHIOXBBIOBYIDR-UHFFFAOYSA-N 0.000 description 1
- AEEBRQAGAXTHPN-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C=1C=2CCCC3=CC=CC=C3C=2N=NC=1N1N=C(N)N=C1NC(C=C1)=CC=C1N(CC1)CCC1N1CCCC1 AEEBRQAGAXTHPN-UHFFFAOYSA-N 0.000 description 1
- GNSSWQBTKXHVQE-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C(C)C)CCN1CC(C=C1)=CC=C1NC1=NC(N)=NN1C(N=N1)=CC2=C1C1=CC=CC=C1CCC2 GNSSWQBTKXHVQE-UHFFFAOYSA-N 0.000 description 1
- BEBHMONXGYGPJT-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[4-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]phenyl]-1,2,4-triazole-3,5-diamine Chemical compound C=1C=2CCCC3=CC=CC=C3C=2N=NC=1N1N=C(N)N=C1NC(C=C1)=CC=C1CN(CC1)CCC1N1CCCC1 BEBHMONXGYGPJT-UHFFFAOYSA-N 0.000 description 1
- WQKMHBJIDYZKCJ-UHFFFAOYSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-5-n-[5-methyl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridin-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound CC1=CC(NC=2N(N=C(N)N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)=CN=C1N(CC1)CCC1N1CCCC1 WQKMHBJIDYZKCJ-UHFFFAOYSA-N 0.000 description 1
- MXVTUUXJXGDKJQ-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-3-n-spiro[1,3-dioxolane-2,6'-5,7,8,9-tetrahydrocyclohepta[b]pyridine]-3'-yl-1,2,4-triazole-3,5-diamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1NC(C=C1C2)=CN=C1CCCC12OCCO1 MXVTUUXJXGDKJQ-UHFFFAOYSA-N 0.000 description 1
- YBLHCKYMJTWERF-UHFFFAOYSA-N 1-(9-chloro-6,7-dihydro-5h-benzo[4,5]cyclohepta[1,2-d]pyridazin-3-yl)-3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=C(Cl)C=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 YBLHCKYMJTWERF-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- YBVZBGHVXFZEEF-UHFFFAOYSA-N 1-benzo[b][1,4]benzothiazepin-6-yl-3-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2C3=CC=CC=C3SC3=CC=CC=C3N=2)C(N)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 YBVZBGHVXFZEEF-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- JLVWPQILIITKON-UHFFFAOYSA-N 1h-cyclohepta[c]pyridazine Chemical compound C1=CC=CC=C2NN=CC=C21 JLVWPQILIITKON-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YQGHJCYLMLPCCB-UHFFFAOYSA-N 2,4-diaminopyrimidin-5-ol Chemical compound NC1=NC=C(O)C(N)=N1 YQGHJCYLMLPCCB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- XFDJLNIZMXEACH-UHFFFAOYSA-N 3-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound N1NC(N)=NC1(N)C(C=C1F)=CC=C1OCCN1CCCC1 XFDJLNIZMXEACH-UHFFFAOYSA-N 0.000 description 1
- YABJHCFPCRFIAW-UHFFFAOYSA-N 3-[3-fluoro-4-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound FC=1C=C(C=CC1N1CCC(CC1)CN1CCCC1)C1(NNC(=N1)N)N YABJHCFPCRFIAW-UHFFFAOYSA-N 0.000 description 1
- DYBCQBCMYWVJOA-UHFFFAOYSA-N 3-[4-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-3-fluorophenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound FC=1C=C(C=CC1N1CC2N(CC1)CCCC2)C2(NNC(=N2)N)N DYBCQBCMYWVJOA-UHFFFAOYSA-N 0.000 description 1
- XIOZSCHMKDRSBG-UHFFFAOYSA-N 3-[4-(1,3-dihydroisoindol-2-yl)-3-fluorophenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound FC=1C=C(C=CC1N1CC2=CC=CC=C2C1)C1(NNC(=N1)N)N XIOZSCHMKDRSBG-UHFFFAOYSA-N 0.000 description 1
- GPRGKPAKPYZMHG-UHFFFAOYSA-N 3-[4-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1=CC=C(C2(N)N=C(N)NN2)C=C1 GPRGKPAKPYZMHG-UHFFFAOYSA-N 0.000 description 1
- XEJZLSXCDGJVDB-JUCUUEBMSA-N 3-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-fluorophenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound FC=1C=C(C=CC1N1C[C@H]2CCCC[C@@H]2CC1)C1(NNC(=N1)N)N XEJZLSXCDGJVDB-JUCUUEBMSA-N 0.000 description 1
- BCZZVFSMLLFQOL-UHFFFAOYSA-N 3-[4-[3-(4-cyclopentylpiperazin-1-yl)prop-1-enyl]phenyl]-1,2-dihydro-1,2,4-triazole-3,5-diamine Chemical compound C1(CCCC1)N1CCN(CC1)CC=CC1=CC=C(C=C1)C1(NNC(=N1)N)N BCZZVFSMLLFQOL-UHFFFAOYSA-N 0.000 description 1
- ANULPDIYDIPAFY-UHFFFAOYSA-N 3-[5-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]pyridin-2-yl]benzonitrile Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1C1=CC=CC(C#N)=C1 ANULPDIYDIPAFY-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- CRPQHUZTWKECLW-UHFFFAOYSA-N 3-n-(2-cyclopentyl-3,4-dihydro-1h-isoquinolin-7-yl)-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C2)=CC=C1CCN2C1CCCC1 CRPQHUZTWKECLW-UHFFFAOYSA-N 0.000 description 1
- RVFYKZPQPXAGCG-UHFFFAOYSA-N 3-n-(6-cyclopentyl-7,8-dihydro-5h-1,6-naphthyridin-3-yl)-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C2)=CN=C1CCN2C1CCCC1 RVFYKZPQPXAGCG-UHFFFAOYSA-N 0.000 description 1
- DDDJMWOAYLIOCA-UHFFFAOYSA-N 3-n-[2-(cyclopropylmethyl)-3,4-dihydro-1h-isoquinolin-7-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C2)=CC=C1CCN2CC1CC1 DDDJMWOAYLIOCA-UHFFFAOYSA-N 0.000 description 1
- XNGWFZNJFKCRFL-UHFFFAOYSA-N 3-n-[3-chloro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1Cl)=CC=C1N(CC1)CCC1N1CCCC1 XNGWFZNJFKCRFL-UHFFFAOYSA-N 0.000 description 1
- MPCIATAFKYYMLE-UHFFFAOYSA-N 3-n-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-1-(7-methyl-5,6-dihydropyridazino[4,3-d][1]benzazepin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N=C2C3=CC=CC=C3N(C)CCC2=CC=1N(C(=N1)N)N=C1NC(C=C1F)=CC=C1OCCN1CCCC1 MPCIATAFKYYMLE-UHFFFAOYSA-N 0.000 description 1
- IZFBJEBORUKAIH-UHFFFAOYSA-N 3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1-(4-phenyl-6,7-dihydro-5h-benzo[1,2]cyclohepta[3,4-c]pyridin-2-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=C3C4=CC=CC=C4CCCC3=C(C=3C=CC=CC=3)C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 IZFBJEBORUKAIH-UHFFFAOYSA-N 0.000 description 1
- IHYWAUYWBKJYEL-UHFFFAOYSA-N 3-n-[3-fluoro-4-(4-pyrrolidin-1-ylpiperidin-1-yl)phenyl]-1-spiro[chromeno[4,3-c]pyridazine-5,1'-cyclopentane]-3-yl-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC3=C(C4(CCCC4)OC4=CC=CC=C43)C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1N1CCCC1 IHYWAUYWBKJYEL-UHFFFAOYSA-N 0.000 description 1
- GLYUBEAPVJBNQJ-UHFFFAOYSA-N 3-n-[3-fluoro-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1-spiro[chromeno[4,3-c]pyridazine-5,1'-cyclopentane]-3-yl-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C)CCN1C1CCN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC4=C(C5(CCCC5)OC5=CC=CC=C54)C=3)=CC=2)F)CC1 GLYUBEAPVJBNQJ-UHFFFAOYSA-N 0.000 description 1
- YPGFJEICXFCXAU-UHFFFAOYSA-N 3-n-[4-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl)-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C(F)C(N3CC4CCCCN4CC3)=CC=2)N=C1N YPGFJEICXFCXAU-UHFFFAOYSA-N 0.000 description 1
- PKWLHGZQFOAILW-UHFFFAOYSA-N 3-n-[4-(3,4,6,7,8,9,10,10a-octahydro-1h-pyrazino[1,2-a]azepin-2-yl)-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C(F)C(N3CC4CCCCCN4CC3)=CC=2)N=C1N PKWLHGZQFOAILW-UHFFFAOYSA-N 0.000 description 1
- CGNRTFAVFAXDCG-UHFFFAOYSA-N 3-n-[4-(4-aminopiperidin-1-yl)-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 CGNRTFAVFAXDCG-UHFFFAOYSA-N 0.000 description 1
- YAVIEINEPHPNAI-UHFFFAOYSA-N 3-n-[4-(4-cyclohexylpiperazin-1-yl)-3-fluorophenyl]-1-(4-phenyl-6,7-dihydro-5h-benzo[1,2]cyclohepta[3,4-c]pyridin-2-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=C3C4=CC=CC=C4CCCC3=C(C=3C=CC=CC=3)C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCN1C1CCCCC1 YAVIEINEPHPNAI-UHFFFAOYSA-N 0.000 description 1
- LRLFOGMXRZPPID-UHFFFAOYSA-N 3-n-[4-(4-cyclohexylpiperazin-1-yl)-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyrimidin-2-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=C3C4=CC=CC=C4CCCC3=CN=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCN1C1CCCCC1 LRLFOGMXRZPPID-UHFFFAOYSA-N 0.000 description 1
- FEPKMFOIKNBUNR-UHFFFAOYSA-N 3-n-[4-(4-cyclohexylpiperazin-1-yl)-3-fluorophenyl]-1-(7-methyl-5,6-dihydropyridazino[4,3-d][1]benzazepin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N=C2C3=CC=CC=C3N(C)CCC2=CC=1N(C(=N1)N)N=C1NC(C=C1F)=CC=C1N(CC1)CCN1C1CCCCC1 FEPKMFOIKNBUNR-UHFFFAOYSA-N 0.000 description 1
- CSKHLGGKJBXURR-UHFFFAOYSA-N 3-n-[4-(4-cyclopentylpiperazin-1-yl)-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCN1C1CCCC1 CSKHLGGKJBXURR-UHFFFAOYSA-N 0.000 description 1
- KEZCNCFLTHGLQC-UHFFFAOYSA-N 3-n-[4-[(4-cyclopentylpiperazin-1-yl)methyl]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1CN(CC1)CCN1C1CCCC1 KEZCNCFLTHGLQC-UHFFFAOYSA-N 0.000 description 1
- OLXGIKSSUSFDJS-DENIHFKCSA-N 3-n-[4-[(4ar,8as)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=C(F)C(N3C[C@H]4CCCC[C@@H]4CC3)=CC=2)N=C1N OLXGIKSSUSFDJS-DENIHFKCSA-N 0.000 description 1
- NWPKFKSBWIDBFC-UHFFFAOYSA-N 3-n-[4-[1-(cyclopropylmethyl)piperidin-4-yl]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C(CC1)CCN1CC1CC1 NWPKFKSBWIDBFC-UHFFFAOYSA-N 0.000 description 1
- BCQHAUURKBYAOX-UHFFFAOYSA-N 3-n-[4-[2-[cyclopentyl(methyl)amino]ethoxy]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=1C=C(NC2=NN(C(N)=N2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C=CC=1OCCN(C)C1CCCC1 BCQHAUURKBYAOX-UHFFFAOYSA-N 0.000 description 1
- QXIYYRYGDASZQY-UHFFFAOYSA-N 3-n-[4-[3-(diethylamino)pyrrolidin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(CC)CC)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 QXIYYRYGDASZQY-UHFFFAOYSA-N 0.000 description 1
- MZHJIFFPUFUSRA-UHFFFAOYSA-N 3-n-[4-[3-[3-(diethylamino)pyrrolidin-1-yl]prop-1-enyl]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(CC)CC)CCN1CC=CC(C=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 MZHJIFFPUFUSRA-UHFFFAOYSA-N 0.000 description 1
- AYSKRQNEHOYERH-UHFFFAOYSA-N 3-n-[4-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]phenyl]-1-(6,7-dihydro-5h-benzo[1,2]cyclohepta[3,4-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C2=C1C(N1N=C(NC=3C=CC(=CC=3)N3CCN(CC3)C3C4CCC(C4)C3)N=C1N)=NC=N2 AYSKRQNEHOYERH-UHFFFAOYSA-N 0.000 description 1
- OBYNKABBKHTYMH-UHFFFAOYSA-N 3-n-[4-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=CC(=CC=2)N2CCN(CC2)C2C3CCC(C3)C2)N=C1N OBYNKABBKHTYMH-UHFFFAOYSA-N 0.000 description 1
- QYQJKWDVYSHWBD-UHFFFAOYSA-N 3-n-[4-[4-(5-cyclohexyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrol-3-yl)piperidin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCC1C(C1C2)NCC1CN2C1CCCCC1 QYQJKWDVYSHWBD-UHFFFAOYSA-N 0.000 description 1
- FITJNSGULIGXNX-UHFFFAOYSA-N 3-n-[4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1F)=CC=C1N(CC1)CCN1CC1CC1 FITJNSGULIGXNX-UHFFFAOYSA-N 0.000 description 1
- WUAMPRNWUBCPQN-UHFFFAOYSA-N 3-n-[4-[4-(diethylamino)piperidin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[1,2]cyclohepta[3,4-d]pyrimidin-4-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N(CC)CC)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2C3=C(C4=CC=CC=C4CCC3)N=CN=2)C(N)=N1 WUAMPRNWUBCPQN-UHFFFAOYSA-N 0.000 description 1
- NUKSSMOLXNOYBZ-UHFFFAOYSA-N 3-n-[4-[4-(diethylamino)piperidin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CC(N(CC)CC)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 NUKSSMOLXNOYBZ-UHFFFAOYSA-N 0.000 description 1
- SRHMZFGEFMHIIQ-UHFFFAOYSA-N 3-n-[4-[4-[cyclopentyl(methyl)amino]piperidin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CN(C=2C(=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)F)CCC1N(C)C1CCCC1 SRHMZFGEFMHIIQ-UHFFFAOYSA-N 0.000 description 1
- KGBQDBVMDMBUNZ-UHFFFAOYSA-N 3-n-[6-(1,3-benzodioxol-5-yl)pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=NC(=CC=2)C=2C=C3OCOC3=CC=2)N=C1N KGBQDBVMDMBUNZ-UHFFFAOYSA-N 0.000 description 1
- HPDTXXMMLYGFDO-UHFFFAOYSA-N 3-n-[6-(3-aminophenyl)pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1C1=CC=CC(N)=C1 HPDTXXMMLYGFDO-UHFFFAOYSA-N 0.000 description 1
- RCUIWKCSSSOFIM-UHFFFAOYSA-N 3-n-[6-(4-cyclopentyl-1,4-diazepan-1-yl)pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1N(CC1)CCCN1C1CCCC1 RCUIWKCSSSOFIM-UHFFFAOYSA-N 0.000 description 1
- SWBASJGLARCDLG-UHFFFAOYSA-N 3-n-[6-(6-aminopyridin-3-yl)pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1C1=CC=C(N)N=C1 SWBASJGLARCDLG-UHFFFAOYSA-N 0.000 description 1
- SVPUXNUAENQSSV-IBGZPJMESA-N 3-n-[6-[(3s)-4-(cyclopropylmethyl)-3-methylpiperazin-1-yl]pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C([C@@H]1C)N(C=2N=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)CCN1CC1CC1 SVPUXNUAENQSSV-IBGZPJMESA-N 0.000 description 1
- YQBHBUMAONEHKC-UHFFFAOYSA-N 3-n-[6-[3-(diethylamino)pyrrolidin-1-yl]pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1C(N(CC)CC)CCN1C(N=C1)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 YQBHBUMAONEHKC-UHFFFAOYSA-N 0.000 description 1
- OJZSANMAXNQZTJ-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)-1,4-diazepan-1-yl]pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=NC(=CC=2)N2CCN(CCC2)C2C3CCC(C3)C2)N=C1N OJZSANMAXNQZTJ-UHFFFAOYSA-N 0.000 description 1
- JNAXAIRSTOFJBG-UHFFFAOYSA-N 3-n-[6-[4-(3-bicyclo[2.2.1]heptanyl)piperazin-1-yl]pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C1CCC2=CC=CC=C2C(N=N2)=C1C=C2N1N=C(NC=2C=NC(=CC=2)N2CCN(CC2)C2C3CCC(C3)C2)N=C1N JNAXAIRSTOFJBG-UHFFFAOYSA-N 0.000 description 1
- OJDMUMDIHGUEDO-UHFFFAOYSA-N 3-n-[6-[4-(cyclopropylmethyl)piperazin-1-yl]pyridin-3-yl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=N1)=CC=C1N(CC1)CCN1CC1CC1 OJDMUMDIHGUEDO-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RNJOKCPFLQMDEC-UHFFFAOYSA-N 4(R),8-dimethyl-trans-2-nonenoyl-CoA Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NVOJQXYKTOVXSZ-UHFFFAOYSA-N 4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]-n-(2-methoxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCOC)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 NVOJQXYKTOVXSZ-UHFFFAOYSA-N 0.000 description 1
- GDVUXCBPQWQYGV-UHFFFAOYSA-N 4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]-n-[2-(dimethylamino)ethyl]benzamide Chemical compound C1=CC(C(=O)NCCN(C)C)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 GDVUXCBPQWQYGV-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- JNEQAGJJLJCKSR-UHFFFAOYSA-N 5-[4-(4-cyclohexylpiperazin-1-yl)phenyl]-2-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-1H-1,2,4-triazole-3,5-diamine Chemical compound C1(CCCCC1)N1CCN(CC1)C1=CC=C(C=C1)C1(NN(C(=N1)N)C1=CC2=C(N=N1)C1=C(CCC2)C=CC=C1)N JNEQAGJJLJCKSR-UHFFFAOYSA-N 0.000 description 1
- ZUKVAJPKSMDPAC-UHFFFAOYSA-N 5-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]-2-(4-pyrrolidin-1-ylpiperidin-1-yl)benzonitrile Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1C#N)=CC=C1N(CC1)CCC1N1CCCC1 ZUKVAJPKSMDPAC-UHFFFAOYSA-N 0.000 description 1
- HBWNPOOEIODZSZ-UHFFFAOYSA-N 5-n-[4-[(4-cyclopentylpiperazin-1-yl)methyl]phenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=1C=2CCCC3=CC=CC=C3C=2N=NC=1N1N=C(N)N=C1NC(C=C1)=CC=C1CN(CC1)CCN1C1CCCC1 HBWNPOOEIODZSZ-UHFFFAOYSA-N 0.000 description 1
- PJYNCWDTTILWPH-UHFFFAOYSA-N 5-n-[4-[4-(cyclopropylmethyl)piperazin-1-yl]-3-fluorophenyl]-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazole-3,5-diamine Chemical compound C=1C=2CCCC3=CC=CC=C3C=2N=NC=1N1N=C(N)N=C1NC(C=C1F)=CC=C1N(CC1)CCN1CC1CC1 PJYNCWDTTILWPH-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010068532 5q minus syndrome Diseases 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000033775 Basophilic Acute Leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102000006313 Cyclin D3 Human genes 0.000 description 1
- 108010058545 Cyclin D3 Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 241000514744 Cyclina Species 0.000 description 1
- 241000065675 Cyclops Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 description 1
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 101150113453 Gsk3a gene Proteins 0.000 description 1
- 108010033152 HSP90 Heat-Shock Proteins Proteins 0.000 description 1
- 102000007011 HSP90 Heat-Shock Proteins Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000650322 Homo sapiens E3 ubiquitin-protein ligase Arkadia Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101001026882 Homo sapiens Serine/threonine-protein kinase D2 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100351501 Mus musculus Cbfb gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- PNXVYHRJZVQRQH-UHFFFAOYSA-N N-[3-[5-[[5-amino-1-(3,4-diazatricyclo[9.4.0.02,7]pentadeca-1(15),2,4,6,11,13-hexaen-5-yl)-1,2,4-triazol-3-yl]amino]pyridin-2-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2N=CC(NC3=NN(C(N)=N3)C=3N=NC=4C5=CC=CC=C5CCCC=4C=3)=CC=2)=C1 PNXVYHRJZVQRQH-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- YLKNZTMMXPFLCF-UHFFFAOYSA-N N=1NC(CC=2C=1C=CC=CC=2)=O Chemical compound N=1NC(CC=2C=1C=CC=CC=2)=O YLKNZTMMXPFLCF-UHFFFAOYSA-N 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- KOPHVNWKPLFWSN-UHFFFAOYSA-N O1CCOC11CCC2=NC=CC=C2CC1 Chemical compound O1CCOC11CCC2=NC=CC=C2CC1 KOPHVNWKPLFWSN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000012247 Oligodendroglial tumor Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 102100036142 Polycystin-2 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 101150071831 RPS6KA1 gene Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 201000011648 T-cell childhood lymphoblastic lymphoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- JMZJBCNHUJOLER-AYQCGTONSA-N [(4as,4br,6as,8s,10as,10bs,12as)-10a,12a-dimethyl-2-oxo-3,4,4a,4b,5,6,6a,7,8,9,10,10b,11,12-tetradecahydro-1h-naphtho[2,1-f]quinolin-8-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@H]3CCC(=O)N1)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 JMZJBCNHUJOLER-AYQCGTONSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- ABGDBHODICJQMU-UHFFFAOYSA-N [4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]phenyl]-(4-cyclopentylpiperazin-1-yl)methanone Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C(=O)N(CC1)CCN1C1CCCC1 ABGDBHODICJQMU-UHFFFAOYSA-N 0.000 description 1
- FOLCRIZNXBFENG-UHFFFAOYSA-N [4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone Chemical compound N=1N(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=NC=1NC(C=C1)=CC=C1C(=O)N(CC1)CCC1N1CCCC1 FOLCRIZNXBFENG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
- 208000010816 acute myeloblastic leukemia without maturation Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 208000018420 bone fibrosarcoma Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 201000007476 breast mucinous carcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FLGMAMYMYDIKLE-UHFFFAOYSA-N chloro hypochlorite;phosphane Chemical compound P.ClOCl FLGMAMYMYDIKLE-UHFFFAOYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 108010010201 core binding factor alpha Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000023437 ependymal tumor Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PKWIYNIDEDLDCJ-UHFFFAOYSA-N guanazole Chemical compound NC1=NNC(N)=N1 PKWIYNIDEDLDCJ-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 208000027671 high grade ependymoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 229940036646 iodine-131-tositumomab Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000002350 malignant ciliary body melanoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- ROSJKFFLIXTTAW-UHFFFAOYSA-N n,n-bis(2-chloroethyl)aniline Chemical compound ClCCN(CCCl)C1=CC=CC=C1 ROSJKFFLIXTTAW-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000004213 neurilemma Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 102000027452 oncogenic receptor tyrosine kinases Human genes 0.000 description 1
- 108091008822 oncogenic receptor tyrosine kinases Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical group O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 206010035059 pineocytoma Diseases 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- RYHCHKWOENFKPL-UHFFFAOYSA-N tert-butyl n-[1-[4-[[5-amino-1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-1,2,4-triazol-3-yl]amino]-2-fluorophenyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C(C(=C1)F)=CC=C1NC1=NN(C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)C(N)=N1 RYHCHKWOENFKPL-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14544809P | 2009-01-16 | 2009-01-16 | |
| US61/145,448 | 2009-01-16 | ||
| PCT/US2010/021275 WO2010083465A1 (en) | 2009-01-16 | 2010-01-15 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011132118A RU2011132118A (ru) | 2013-02-27 |
| RU2555326C2 true RU2555326C2 (ru) | 2015-07-10 |
Family
ID=41683427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011132118/15A RU2555326C2 (ru) | 2009-01-16 | 2010-01-15 | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8546433B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2387395B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5858789B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102281875B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010204578B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1007046B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2749843C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2528032T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2387395T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2387395E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2555326C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG172997A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010083465A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009507080A (ja) * | 2005-09-07 | 2009-02-19 | リゲル ファーマシューティカルズ，インコーポレーテッド | Ａｘｌ阻害剤として有用なトリアゾール誘導体 |
| US8012965B2 (en) | 2006-12-29 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ES2607065T3 (es) | 2006-12-29 | 2017-03-29 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| AU2007342007A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as Axl inhibitors |
| AU2007341937B2 (en) | 2006-12-29 | 2013-07-11 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
| US7935693B2 (en) * | 2007-10-26 | 2011-05-03 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
| HRP20130045T1 (hr) | 2008-07-09 | 2013-02-28 | Rigel Pharmaceuticals, Inc. | Premošteni bicikliäśki heteroaril supstituirani triazoli koji su korisni kao axl inhibitori |
| JP4644273B2 (ja) * | 2008-07-15 | 2011-03-02 | 本田技研工業株式会社 | 車両周辺監視装置 |
| JP5858789B2 (ja) | 2009-01-16 | 2016-02-10 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
| EP2484678B1 (en) | 2009-09-28 | 2015-01-21 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors |
| GB201207722D0 (en) | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| CA2879542A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
| CN105916506B (zh) | 2013-11-20 | 2020-01-07 | 圣诺康生命科学公司 | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
| EP3074390B1 (en) | 2013-11-27 | 2020-07-08 | SignalChem Lifesciences Corporation | Aminopyridine derivatives as tam family kinase inhibitors |
| US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
| WO2015156674A2 (en) * | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015161230A1 (en) * | 2014-04-19 | 2015-10-22 | Massachusetts Institute Of Technology | Methods of reducing kinase inhibitor resistance |
| GB201420285D0 (en) | 2014-11-14 | 2014-12-31 | Bergenbio As | Process |
| GB201509338D0 (en) * | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CN106083764B (zh) * | 2016-07-11 | 2018-09-18 | 上海皓元生物医药科技有限公司 | 一种用于制备axl抑制剂的高纯度中间体的手性拆分方法 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| MX2020007130A (es) * | 2017-11-04 | 2021-02-15 | Aravive Biologics Inc | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. |
| JP7460639B2 (ja) * | 2018-09-18 | 2024-04-02 | シグナルケム・ライフサイエンシーズ・コーポレイション | 血液癌を治療するための併用療法 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| JPWO2022220227A1 (cg-RX-API-DMAC7.html) * | 2021-04-14 | 2022-10-20 | ||
| GB202209285D0 (en) | 2022-06-24 | 2022-08-10 | Bergenbio Asa | Dosage regimen for AXL inhibitor |
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057562A1 (en) * | 2006-11-06 | 2008-05-15 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008083367A2 (en) * | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1403866A (en) | 1971-12-06 | 1975-08-28 | Wyeth John & Brother Ltd | Derivatives of 3-amino-1,2,4-triazoles |
| US4512992A (en) | 1980-06-13 | 1985-04-23 | Burroughs Wellcome Co. | Treatment with dialkoxy pyridopyrimidine compounds |
| WO1990007926A1 (en) | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| US6258360B1 (en) | 1989-05-04 | 2001-07-10 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
| EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| GB9918180D0 (en) | 1999-08-02 | 1999-10-06 | Smithkline Beecham Plc | Novel compositions |
| BR0116792A (pt) | 2000-12-22 | 2004-02-17 | Ortho Mcneil Pharm Inc | Derivados de diamina de triazol substituìdos como inibidores de quinase |
| DE10123586A1 (de) | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| TWI335221B (en) | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| JP2005533748A (ja) | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ，インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
| BR0309688A (pt) | 2002-05-03 | 2005-02-22 | Janssen Pharmaceutica Nv | Microemulsões poliméricas |
| AU2003252395A1 (en) | 2002-08-06 | 2004-03-11 | Toray Industries, Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| WO2004039955A2 (en) | 2002-10-29 | 2004-05-13 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20070149560A1 (en) | 2003-03-14 | 2007-06-28 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| KR20060027338A (ko) | 2003-06-12 | 2006-03-27 | 아스텔라스세이야쿠 가부시키가이샤 | 벤즈 아미드 유도체 또는 그 염 |
| PE20050338A1 (es) | 2003-08-06 | 2005-05-16 | Vertex Pharma | Compuestos de aminotriazoles como inhibidores de proteina quinasas |
| JP2007519711A (ja) | 2004-01-30 | 2007-07-19 | アブ サイエンス | チロシンキナーゼ阻害薬としての２−（３−置換−アリール）アミノ−４−アリール−チアゾール |
| US20060100259A1 (en) | 2004-02-11 | 2006-05-11 | Palmer David C | Process for the preparation of substituted triazole compounds |
| WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| MX2007001727A (es) | 2004-08-13 | 2007-04-20 | Genentech Inc | Compuestos a base de 2-amido-tiazol que exhiben actividad inhibidora de enzima que utiliza atp y composiciones y usos de los mismos. |
| US7329652B2 (en) | 2004-09-17 | 2008-02-12 | Vertex Pharamaceuticals Incorporated | Diaminotriazole compounds useful as protein kinase inhibitors |
| US7645775B2 (en) | 2004-10-21 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Triazoles useful as inhibitors of protein kinases |
| US20060166936A1 (en) | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
| CN101106983A (zh) | 2004-11-24 | 2008-01-16 | 诺瓦提斯公司 | JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合 |
| JP2009507080A (ja) | 2005-09-07 | 2009-02-19 | リゲル ファーマシューティカルズ，インコーポレーテッド | Ａｘｌ阻害剤として有用なトリアゾール誘導体 |
| JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| WO2007118149A2 (en) | 2006-04-07 | 2007-10-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| US8097630B2 (en) | 2006-10-10 | 2012-01-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors |
| FR2908131B1 (fr) | 2006-11-03 | 2009-01-09 | Univ Haute Alsace Etablissemen | Derives d'aminobenzocycloheptene,leurs procedes de preparation et leur utilisation en therapeutique |
| JP2008130120A (ja) | 2006-11-17 | 2008-06-05 | Sharp Corp | 光ピックアップ装置 |
| US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
| AU2007342007A1 (en) | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Substituted triazoles useful as Axl inhibitors |
| US8012965B2 (en) | 2006-12-29 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ES2607065T3 (es) | 2006-12-29 | 2017-03-29 | Rigel Pharmaceuticals, Inc. | Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl |
| ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
| CA2690653A1 (en) | 2007-06-15 | 2008-12-24 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| US7935693B2 (en) | 2007-10-26 | 2011-05-03 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| ES2537480T3 (es) | 2008-07-09 | 2015-06-08 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl |
| HRP20130045T1 (hr) | 2008-07-09 | 2013-02-28 | Rigel Pharmaceuticals, Inc. | Premošteni bicikliäśki heteroaril supstituirani triazoli koji su korisni kao axl inhibitori |
| JP5858789B2 (ja) * | 2009-01-16 | 2016-02-10 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬 |
-
2010
- 2010-01-15 JP JP2011546409A patent/JP5858789B2/ja active Active
- 2010-01-15 PT PT107006868T patent/PT2387395E/pt unknown
- 2010-01-15 SG SG2011051174A patent/SG172997A1/en unknown
- 2010-01-15 WO PCT/US2010/021275 patent/WO2010083465A1/en not_active Ceased
- 2010-01-15 EP EP10700686.8A patent/EP2387395B1/en active Active
- 2010-01-15 AU AU2010204578A patent/AU2010204578B2/en active Active
- 2010-01-15 BR BRPI1007046-0A patent/BRPI1007046B1/pt active IP Right Grant
- 2010-01-15 ES ES10700686.8T patent/ES2528032T3/es active Active
- 2010-01-15 US US12/688,746 patent/US8546433B2/en active Active
- 2010-01-15 PL PL10700686T patent/PL2387395T3/pl unknown
- 2010-01-15 CA CA2749843A patent/CA2749843C/en active Active
- 2010-01-15 RU RU2011132118/15A patent/RU2555326C2/ru active
- 2010-01-15 CN CN201080004818.0A patent/CN102281875B/zh active Active
-
2013
- 2013-06-03 US US13/908,874 patent/US20130338161A1/en not_active Abandoned
-
2014
- 2014-10-10 JP JP2014208912A patent/JP2015007135A/ja active Pending
-
2016
- 2016-03-22 US US15/077,648 patent/US20170042891A1/en not_active Abandoned
-
2019
- 2019-03-12 US US16/351,130 patent/US20190336500A1/en not_active Abandoned
-
2021
- 2021-06-18 US US17/351,996 patent/US20210379064A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057562A1 (en) * | 2006-11-06 | 2008-05-15 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008083367A2 (en) * | 2006-12-29 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| ZHANG YX et al, AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 2008 Mar 15;68(6):1905-15 онлайн [найдено 15.01.2014], найдено из Интернет http://www.ncbi.nlm.nih.gov/pubmed/18339872 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2528032T3 (es) | 2015-02-03 |
| US20170042891A1 (en) | 2017-02-16 |
| US20100196511A1 (en) | 2010-08-05 |
| PT2387395E (pt) | 2015-02-04 |
| WO2010083465A1 (en) | 2010-07-22 |
| PL2387395T3 (pl) | 2015-03-31 |
| CA2749843C (en) | 2017-09-05 |
| US20130338161A1 (en) | 2013-12-19 |
| US20210379064A1 (en) | 2021-12-09 |
| CN102281875B (zh) | 2017-09-22 |
| CA2749843A1 (en) | 2011-07-22 |
| AU2010204578A1 (en) | 2011-07-28 |
| RU2011132118A (ru) | 2013-02-27 |
| JP2012515225A (ja) | 2012-07-05 |
| JP2015007135A (ja) | 2015-01-15 |
| US20190336500A1 (en) | 2019-11-07 |
| SG172997A1 (en) | 2011-08-29 |
| JP5858789B2 (ja) | 2016-02-10 |
| US8546433B2 (en) | 2013-10-01 |
| BRPI1007046A2 (pt) | 2015-07-21 |
| BRPI1007046B1 (pt) | 2019-07-16 |
| EP2387395B1 (en) | 2014-10-15 |
| CN102281875A (zh) | 2011-12-14 |
| EP2387395A1 (en) | 2011-11-23 |
| HK1164146A1 (en) | 2012-09-21 |
| AU2010204578B2 (en) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2555326C2 (ru) | ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА | |
| JP7549627B2 (ja) | Ａｘｌインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 | |
| EP2326641B1 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| EP2074115B1 (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors | |
| EP2114954B1 (en) | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| EP2078010B1 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| EP2476679B1 (en) | Substituted triazoles useful as AXL inhibitors | |
| CA2779105C (en) | Kinase inhibitors | |
| KR20180129783A (ko) | Ｒｓｋ 억제제로서 유용한 카르복사미드 유도체 | |
| HK1164146B (en) | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | |
| HK40049850A (en) | Combination therapy | |
| HK1174631B (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | |
| HK1158625B (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |